Literature DB >> 16216007

Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance.

Shaun McKenzie1, Natasha Kyprianou.   

Abstract

The ability of a tumor cell population to grow exponentially represents an imbalance between cellular proliferation and cellular attrition. There is an overwhelming body of evidence suggesting the ability of tumor cells to avoid programmed cellular attrition, or apoptosis, is a major molecular force driving the progression of human tumors. Apoptotic evasion represents one of the true hallmarks of cancer and appears to be a vital component in the immunogenic, chemotherapeutic, and radiotherapeutic resistance that characterizes the most aggressive of human cancers [Hanahan and Weinberg, 2000]. The challenges in the development of effective treatment modalities for advanced prostate cancer represent a classic paradigm of the functional significance of anti-apoptotic pathways in the development of therapeutic resistance. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16216007      PMCID: PMC2274918          DOI: 10.1002/jcb.20634

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  120 in total

1.  Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model.

Authors:  Jennifer A Tuxhorn; Stephanie J McAlhany; Feng Yang; Truong D Dang; David R Rowley
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

2.  From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells.

Authors:  H Y Kang; H K Lin; Y C Hu; S Yeh; K E Huang; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

3.  Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.

Authors:  P C Smith; E T Keller
Journal:  Prostate       Date:  2001-06-15       Impact factor: 4.104

4.  Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.

Authors:  M Burchardt; T Burchardt; A Shabsigh; M Ghafar; M W Chen; A Anastasiadis; A de la Taille; A Kiss; R Buttyan
Journal:  Prostate       Date:  2001-09-15       Impact factor: 4.104

5.  Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line.

Authors:  Xin-Hua Liu; Alexander Kirschenbaum; Kang Yu; Shen Yao; Alice C Levine
Journal:  J Biol Chem       Date:  2004-11-18       Impact factor: 5.157

Review 6.  Akt in prostate cancer: possible role in androgen-independence.

Authors:  Paramita M Ghosh; Shazli Malik; Roble Bedolla; Jeffrey I Kreisberg
Journal:  Curr Drug Metab       Date:  2003-12       Impact factor: 3.731

7.  Defining a role for the inhibitors of apoptosis proteins in prostate cancer.

Authors:  K R McEleny; R W G Watson; J M Fitzpatrick
Journal:  Prostate Cancer Prostatic Dis       Date:  2001       Impact factor: 5.554

Review 8.  Bortezomib as a potential treatment for prostate cancer.

Authors:  Christos N Papandreou; Christopher J Logothetis
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 9.  Going malignant: the hypoxia-cancer connection in the prostate.

Authors:  P W Hochachka; J L Rupert; L Goldenberg; M Gleave; P Kozlowski
Journal:  Bioessays       Date:  2002-08       Impact factor: 4.345

Review 10.  Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.

Authors:  J Bogdanos; D Karamanolakis; R Tenta; A Tsintavis; C Milathianakis; C Mitsiades; M Koutsilieris
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

View more
  46 in total

1.  Arsenic-specific stem cell selection during malignant transformation.

Authors:  Erik J Tokar; Wei Qu; Jie Liu; Wei Liu; Mukta M Webber; James M Phang; Michael P Waalkes
Journal:  J Natl Cancer Inst       Date:  2010-03-25       Impact factor: 13.506

2.  Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult.

Authors:  Janet K Hess-Wilson; Hannah K Daly; William A Zagorski; Christopher P Montville; Karen E Knudsen
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

Review 3.  Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.

Authors:  Teodora Ribarska; Klaus-Marius Bastian; Annemarie Koch; Wolfgang A Schulz
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

4.  Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer.

Authors:  Joanne Collazo; Beibei Zhu; Spencer Larkin; Sarah K Martin; Hong Pu; Craig Horbinski; Shahriar Koochekpour; Natasha Kyprianou
Journal:  Cancer Res       Date:  2014-02-07       Impact factor: 12.701

5.  Methylarsonous acid causes oxidative DNA damage in cells independent of the ability to biomethylate inorganic arsenic.

Authors:  Erik J Tokar; Chikara Kojima; Michael P Waalkes
Journal:  Arch Toxicol       Date:  2013-10-05       Impact factor: 5.153

6.  Sensitivity of human prostate cancer cells to chemotherapeutic drugs depends on EndoG expression regulated by promoter methylation.

Authors:  Xiaoying Wang; Volodymyr Tryndyak; Eugene O Apostolov; Xiaoyan Yin; Sudhir V Shah; Igor P Pogribny; Alexei G Basnakian
Journal:  Cancer Lett       Date:  2008-06-18       Impact factor: 8.679

7.  Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases.

Authors:  Canan Akfirat; Xiaotun Zhang; Aviva Ventura; Dror Berel; Mary E Colangelo; Cindy K Miranti; Maryla Krajewska; John C Reed; Celestia S Higano; Lawrence D True; Robert L Vessella; Colm Morrissey; Beatrice S Knudsen
Journal:  J Pathol       Date:  2013-07       Impact factor: 7.996

8.  Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

Authors:  Robert Clarke; Ayesha N Shajahan; Rebecca B Riggins; Younsook Cho; Anatasha Crawford; Jianhua Xuan; Yue Wang; Alan Zwart; Ruchi Nehra; Minetta C Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2009-03       Impact factor: 4.292

9.  Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells.

Authors:  Maria Katsogiannou; Charbel El Boustany; Florian Gackiere; Philippe Delcourt; Anne Athias; Pascal Mariot; Etienne Dewailly; Nathalie Jouy; Christophe Lamaze; Gabriel Bidaux; Brigitte Mauroy; Natalia Prevarskaya; Christian Slomianny
Journal:  PLoS One       Date:  2009-09-18       Impact factor: 3.240

10.  Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.

Authors:  Melanie Mediavilla-Varela; Fabio J Pacheco; Frankis Almaguel; Jossymar Perez; Eva Sahakian; Tracy R Daniels; Lai Sum Leoh; Amelia Padilla; Nathan R Wall; Michael B Lilly; Marino De Leon; Carlos A Casiano
Journal:  Mol Cancer       Date:  2009-08-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.